I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe

In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in eight European Union (EU) member states to estimate 2010/11 influenza vaccine effectiveness (VE) against medical...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2011-11, Vol.6 (11), p.e27622-e27622
Main Authors: Kissling, Esther, Valenciano, Marta, Cohen, Jean Marie, Oroszi, Beatrix, Barret, Anne-Sophie, Rizzo, Caterina, Stefanoff, Pawel, Nunes, Baltazar, Pitigoi, Daniela, Larrauri, Amparo, Daviaud, Isabelle, Horvath, Judit Krisztina, O'Donnell, Joan, Seyler, Thomas, Paradowska-Stankiewicz, Iwona Anna, Pechirra, Pedro, Ivanciuc, Alina Elena, Jiménez-Jorge, Silvia, Savulescu, Camelia, Ciancio, Bruno Christian, Moren, Alain
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age groups
Analysis
Biology
Case-Control Studies
Child
Child, Preschool
Chronic illnesses
Disease
Disease prevention
Epidemiology
Estimates
Europe
Female
Health promotion
Health surveillance
Humans
Immunology
Infant
Infant, Newborn
Infections
Influenza
Influenza A Virus, H1N1 Subtype - immunology
Influenza A Virus, H1N1 Subtype - pathogenicity
Influenza B
Influenza vaccines
Influenza Vaccines - immunology
Influenza, Human - prevention & control
Laboratories
Male
Mathematical models
Medical research
Medicine
Middle Aged
Models, Statistical
Pandemics
Patients
Public health
Regression analysis
Sampling methods
Seasons
Species Specificity
Studies
Target groups
Time Factors
Vaccination
Vaccine efficacy
Vaccines
Young Adult
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in eight European Union (EU) member states to estimate 2010/11 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. Using systematic sampling, practitioners swabbed ILI/ARI patients within seven days of symptom onset. We compared influenza-positive to influenza laboratory-negative patients among those meeting the EU ILI case definition. A valid vaccination corresponded to > 14 days between receiving a dose of vaccine and symptom onset. We used multiple imputation with chained equations to estimate missing values. Using logistic regression with study as fixed effect we calculated influenza VE adjusting for potential confounders. We estimated influenza VE overall, by influenza type, age group and among the target group for vaccination. We included 2019 cases and 2391 controls in the analysis. Adjusted VE was 52% (95% CI 30-67) overall (N = 4410), 55% (95% CI 29-72) against A(H1N1) and 50% (95% CI 14-71) against influenza B. Adjusted VE against all influenza subtypes was 66% (95% CI 15-86), 41% (95% CI -3-66) and 60% (95% CI 17-81) among those aged 0-14, 15-59 and ≥60 respectively. Among target groups for vaccination (N = 1004), VE was 56% (95% CI 34-71) overall, 59% (95% CI 32-75) against A(H1N1) and 63% (95% CI 31-81) against influenza B. Results suggest moderate protection from 2010-11 trivalent influenza vaccines against medically-attended ILI laboratory-confirmed as influenza across Europe. Adjusted and stratified influenza VE estimates are possible with the large sample size of this multi-centre case-control. I-MOVE shows how a network can provide precise summary VE measures across Europe.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0027622